Vericel (VCEL) Cash & Current Investments (2010 - 2026)
Vericel (VCEL) posted Cash & Current Investments of $162.5 million for Q2 2026, up 11.8% sequentially from $145.3 million in Q1 2026, and up 39.03% YoY from $116.9 million in Q2 2025.
Analysis
Vericel (VCEL) Cash & Current Investments (2010 - 2026) Analysis & Trends
Vericel has reported Cash & Current Investments for 15 years, with the latest figure at $162.5 million in Q2 2026.
- Quarterly Cash & Current Investments rose 39.03% year-over-year to $162.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $162.5 million (up 39.03% YoY) and the FY2025 annual result came in at $137.5 million, up 18.32% from the prior year.
- Cash & Current Investments rose to $162.5 million in Q2 2026 per VCEL's latest filing, from $145.3 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $162.5 million in Q2 2026 and troughed at $97.8 million in Q2 2023.
- A 5-year average of $117.0 million and a median of $111.9 million in 2022 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2026: Cash & Current Investments declined 8.35% in 2023, then soared 39.03% in 2026.
- Over 5 years, Cash & Current Investments stood at $119.5 million in 2022, then decreased by 8.35% to $109.6 million in 2023, then climbed by 6.08% to $116.2 million in 2024, then climbed by 18.32% to $137.5 million in 2025, then increased by 18.18% to $162.5 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $162.5 million, $145.3 million, and $137.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 162.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 162.50 Mn |
| Mar 31, 2026 | 145.35 Mn |
| Dec 31, 2025 | 137.50 Mn |
| Sep 30, 2025 | 135.38 Mn |
| Jun 30, 2025 | 116.88 Mn |
| Mar 31, 2025 | 112.90 Mn |
| Dec 31, 2024 | 116.21 Mn |
| Sep 30, 2024 | 101.73 Mn |
| Jun 30, 2024 | 102.51 Mn |
| Mar 31, 2024 | 110.65 Mn |
| Dec 31, 2023 | 109.56 Mn |
| Sep 30, 2023 | 105.34 Mn |
| Jun 30, 2023 | 97.83 Mn |
| Mar 31, 2023 | 119.28 Mn |
| Dec 31, 2022 | 119.54 Mn |
| Sep 30, 2022 | 110.94 Mn |
| Jun 30, 2022 | 100.69 Mn |
| Mar 31, 2022 | 100.55 Mn |
| Dec 31, 2021 | 103.40 Mn |
| Sep 30, 2021 | 98.29 Mn |